New drug cocktail aims to halt aggressive breast cancer

NCT ID NCT07359404

ENROLLING_BY_INVITATION Disease control Sponsor: YING FAN Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, sacituzumab govitecan and bevacizumab, in people with metastatic triple-negative breast cancer that has progressed after at least one prior treatment. The trial will enroll 60 participants across several centers in China. Researchers will first find the safest dose, then measure how long the cancer stays under control and monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab Govitecan and Bevacizumab
What this could lead to: If successful, this combination could offer a new second-line or later treatment option for people with metastatic triple-negative breast cancer, potentially slowing disease progression.
What could go wrong: This is an early Phase II study with only 60 participants, so results may not apply to all patients. The combination may cause significant side effects, and it is not yet known if it improves overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Locations

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.